Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
£ 13.5
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. In particular, the stock is of fair value on EV/EBITDA.
Data is available to registered users only
Buy
Sell